MedTrace Logo

The Acute Effect of Hypericum Perforatum on Short-Term Memory in Healthy Adults

NCT02862236 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2018-09-14

No results posted yet for this study

Summary

Rationale Over-the-counter drugs containing hypericum perforatum (H. perforatum), have been argued to improve memory and sustained attention. So far, these claims have not been supported in human studies. However, previous studies used rather high dosages, and little is known about the acute effect of small dosages.

Objective We evaluated whether an acute treatment with Remotiv 500 and Remotiv 250 (500 or 250 mg of H. perforatum quantified to either 1 or 0.5 mg of hypericin) improved memory, sustained attention, as well as mood and state anxiety in healthy adults.

Method A single dosage, randomized, double blind, placebo-controlled trial was conducted with 82 student participants (33 women). Each participant received placebo in one session and one of two dosages in the other session. Order of the sessions and dosage conditions were randomized between subjects. Participants completed a battery of tasks assessing short-term memory capacity and sustained attention.

Conditions

  • Subclinical Anxious Adults
  • Nootropic Potential of Hypericum and Alprazolam
  • Healthy Adults

Interventions

DRUG

Hypericum perforatum extract

250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.

Sponsors & Collaborators

  • Beer Yaakov - Ness Ziona Mental Health Center

    collaborator OTHER_GOV

  • Prof. Eldad Yechiam

    lead OTHER

Principal Investigators

  • Mili Bar-Shaked, MD · Beer Yaakov - Ness Ziona Mental Health Center

  • Eldad Yechiam, PhD · Technion, Israel Institute of Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-21
Primary Completion
2018-02-02
Completion
2018-02-02

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02862236 on ClinicalTrials.gov